Systematic endoscopic characterization of synchronous esophageal, gastric, and colorectal involvement in multisystem Langerhans cell histiocytosis

Systematic endoscopic characterization of synchronous esophageal, gastric, and colorectal involvement in multisystem Langerhans cell histiocytosis (LCH) provides critical insights into the rare and under-recognized gastrointestinal (GI) manifestations of this disease. Below is a detailed overview of the findings and implications:

### 1. **Rarity and Multisystem Nature of LCH:**

• Adult-onset LCH is uncommon, and gastrointestinal involvement is particularly rare.
• LCH is a multisystem disease that can affect various organs simultaneously, including the oral cavity, lungs, and GI tract.

### 2. **Endoscopic Findings Across the GI Tract:**

• **Esophageal Involvement:**
• Lesions in the esophagus were characterized by distinct patterns, including:
• Raised plaques with central depressions.
• Radial telangiectasia.
• Barnacle-like satellite nodules.
• These findings are unique and contribute to the recognition of esophageal LCH.
• **Gastric Involvement:**
• Gastric lesions presented with a diverse range of appearances, such as:
• Ulcerative defects.
• Firm submucosal protrusions with surface erosion.
• These findings highlight the variability of gastric LCH manifestations.
• **Colorectal Involvement:**
• Colonic lesions appeared as clustered submucosal masses, with a predilection for the ileocecal and sigmoid regions.
• The submucosal nature of these lesions often made them difficult to detect on superficial examination.

### 3. **Submucosal Predominance and Diagnostic Challenges:**

• Many LCH lesions were predominantly subepithelial, with intact overlying mucosa.
• This submucosal location complicates the ability to diagnose the disease through superficial biopsies.
• A novel endoscopic observation, termed the "mucosal fragmentation sign," was identified during resection. This sign refers to fragile mucosa overlying tumor tissue, likely caused by pressure from expanding submucosal infiltration.

### 4. **Histologic and Molecular Confirmation:**

• Diagnosis of LCH relies on histological confirmation of Langerhans cells, which are positive for markers such as:
• CD1a.
• S100.
• Langerin.
• Additionally, the presence of the BRAF V600E mutation supports the neoplastic nature of adult LCH.

### 5. **Importance of Deep Biopsies:**

• Given the submucosal predominance of LCH lesions, deep biopsies are essential to obtain diagnostic tissue.
• Superficial biopsies may fail to capture the underlying pathology, leading to missed or delayed diagnosis.

### 6. **Imaging Limitations:**

• Conventional imaging methods, including PET scans, often fail to detect mucosal or submucosal GI LCH lesions.
• Endoscopic evaluation is therefore critical for identifying these lesions.

### 7. **Differential Diagnosis and Misdiagnosis Risk:**

• GI LCH may mimic other conditions such as carcinoma, lymphoma, or inflammatory diseases.
• This overlap increases the risk of misdiagnosis, emphasizing the need for heightened clinical awareness.

### 8. **Clinical Implications and Recommendations:**

• **Proactive Endoscopy:**
• Patients with confirmed LCH, even in the absence of digestive symptoms, should undergo systematic gastrointestinal endoscopy to detect potential GI involvement.
• **Recognition of Endoscopic Patterns:**
• Awareness of the characteristic endoscopic findings (e.g., raised plaques, submucosal masses, mucosal fragmentation) can facilitate earlier diagnosis in atypical cases.
• **Multidisciplinary Approach:**
• Collaboration between gastroenterologists, pathologists, and oncologists is crucial for accurate diagnosis and management.

### 9. **Significance of the Case:**

• This case uniquely documents concurrent involvement of the esophagus, stomach, and colon in an adult patient with LCH.
• It underscores the value of systematic endoscopic characterization in identifying widespread GI lesions that may not be apparent on imaging or present with overt symptoms.

### 10. **Conclusion:**

• Systematic endoscopic evaluation is a vital diagnostic tool in detecting synchronous GI involvement in multisystem LCH.
• Early recognition and deep biopsy of characteristic lesions can lead to timely diagnosis and appropriate management, improving outcomes for patients with this rare disease.